Axsome Therapeutics, Inc. · AXSM · Next earnings

Axsome Therapeutics, Inc. reports Monday, Nov 2, 2026

AXSM reports before market open with consensus EPS at $-0.49 and revenue at $258.3M. Last quarter: Axsome reports strong AUVELITY-led growth as pipeline advances

Reports Before market open43 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $-0.49 Calendar consensus
Consensus revenue $258.3M Calendar consensus
Report date Nov 2, 2026 Monday, date estimated
Session Before market open 43 days away

Where AXSM left off: FY2026 Q2

Full report

Axsome reports strong AUVELITY-led growth as pipeline advances

EPS surprise -11.0% Reported $-0.99 vs $-0.89
Revenue surprise -2.2% Reported $216.4M vs $221.1M
Stock move +3.8% Event window
Subsequent drift -5.9% Up to 20 sessions

No new guidance was provided in the supplied analysis; management emphasized continued commercial expansion and pipeline execution.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • AUVELITY’s Alzheimer’s agitation launch may not sustain its early adoption pace.
  • Higher SG&A and sales-force expansion could pressure operating leverage.
  • Payer dynamics, gross-to-net discounts, competition, and regulatory outcomes remain important execution risks.

Questions analysts left open

  • The durability of AUVELITY adoption across long-term care and community settings remains unproven.
  • Gross-to-net discounts, reimbursement, and competitive positioning could affect commercialization economics.
  • Pipeline value depends on regulatory progress and execution across multiple Phase III programs.

Ask FN2 about AXSM next report

Transcript, numbers and history already loaded
What should I watch for in AXSM's next earnings report?How did AXSM guide last quarter, and is consensus above or below that?Give me the bull and bear case going into AXSM earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the AXSM recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent AXSM quarters

All AXSM earnings
+3.8%FY2026 Q2

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.